These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 9887238

  • 41. Tubulin inhibitor AEZS 112 inhibits the growth of experimental human ovarian and endometrial cancers irrespective of caspase inhibition.
    Engel JB, Schönhals T, Weidler C, Häusler S, Krockenberger M, Rieger L, Dietl J, Wischhusen J, Honig A.
    Oncol Rep; 2009 Aug; 22(2):361-7. PubMed ID: 19578778
    [Abstract] [Full Text] [Related]

  • 42. [Regulation of human progesterone receptor isoforms A and B in uterine endometrial carcinoma by estrogen and insulin-like growth factor-1].
    Zhang X, Wei L, Wang J, Tu Z.
    Zhonghua Yi Xue Za Zhi; 2002 Jun 25; 82(12):836-9. PubMed ID: 12126534
    [Abstract] [Full Text] [Related]

  • 43. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A, Schulz H, Emons G, Gründker C.
    Gynecol Endocrinol; 2008 Jun 25; 24(6):331-8. PubMed ID: 18584413
    [Abstract] [Full Text] [Related]

  • 44. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
    Fister S, Günthert AR, Aicher B, Paulini KW, Emons G, Gründker C.
    Cancer Res; 2009 Aug 15; 69(16):6473-81. PubMed ID: 19638591
    [Abstract] [Full Text] [Related]

  • 45. The influence of hormones on CD44 expression in endometrial and breast carcinomas.
    Durst B, Sorg RV, Röder G, Betz B, Beckmann MW, Niederacher D, Bender HG, Dall P.
    Oncol Rep; 2001 Aug 15; 8(5):987-93. PubMed ID: 11496303
    [Abstract] [Full Text] [Related]

  • 46. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
    Wells A, Souto JC, Solava J, Kassis J, Bailey KJ, Turner T.
    Clin Cancer Res; 2002 Apr 15; 8(4):1251-7. PubMed ID: 11948140
    [Abstract] [Full Text] [Related]

  • 47. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G, Sindermann H, Engel J, Schally AV, Gründker C.
    Neuroendocrinology; 2009 Apr 15; 90(1):15-8. PubMed ID: 19521066
    [Abstract] [Full Text] [Related]

  • 48. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers.
    Straub B, Müller M, Krause H, Schrader M, Goessl C, Heicappell R, Miller K.
    Clin Cancer Res; 2001 Aug 15; 7(8):2340-3. PubMed ID: 11489810
    [Abstract] [Full Text] [Related]

  • 49. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
    Yang DC, Jiang XP, Elliott RL, Head JF.
    Anticancer Res; 2001 Aug 15; 21(3B):1777-87. PubMed ID: 11497259
    [Abstract] [Full Text] [Related]

  • 50. Hepatocyte growth factor (HGF) induces invasion of endometrial carcinoma cell lines in vitro.
    Bae-Jump V, Segreti EM, Vandermolen D, Kauma S.
    Gynecol Oncol; 1999 May 15; 73(2):265-72. PubMed ID: 10329045
    [Abstract] [Full Text] [Related]

  • 51. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
    Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser HP, Nagy A, Schulz KD, Grundker C, Schally AV, Emons G.
    Int J Oncol; 2000 Nov 15; 17(5):1063-9. PubMed ID: 11029513
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues.
    Völker P, Gründker C, Schmidt O, Schulz KD, Emons G.
    Am J Obstet Gynecol; 2002 Feb 15; 186(2):171-9. PubMed ID: 11854630
    [Abstract] [Full Text] [Related]

  • 54. Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin.
    Gründker C, Schlotawa L, Viereck V, Emons G.
    Eur J Endocrinol; 2001 Nov 15; 145(5):651-8. PubMed ID: 11720885
    [Abstract] [Full Text] [Related]

  • 55. Antitumor effect of GnRH agonist in epithelial ovarian cancer.
    Kim JH, Park DC, Kim JW, Choi YK, Lew YO, Kim DH, Jung JK, Lim YA, Namkoong SE.
    Gynecol Oncol; 1999 Aug 15; 74(2):170-80. PubMed ID: 10419728
    [Abstract] [Full Text] [Related]

  • 56. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
    Günthert AR, Gründker C, Böttcher B, Emons G.
    Anticancer Res; 2004 Aug 15; 24(3a):1727-32. PubMed ID: 15274347
    [Abstract] [Full Text] [Related]

  • 57. Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium.
    Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T.
    Gynecol Oncol; 1994 Oct 15; 55(1):144-8. PubMed ID: 7959256
    [Abstract] [Full Text] [Related]

  • 58. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP.
    Limonta P, Dondi D, Moretti RM, Maggi R, Motta M.
    J Clin Endocrinol Metab; 1992 Jul 15; 75(1):207-12. PubMed ID: 1320049
    [Abstract] [Full Text] [Related]

  • 59. Cell-associated insulin-like growth factor-binding proteins inhibit insulin-like growth factor-I-induced endometrial cancer cell proliferation.
    Bermont L, Fauconnet S, Lamielle F, Adessi GL.
    Cell Mol Biol (Noisy-le-grand); 2000 Nov 15; 46(7):1173-82. PubMed ID: 11075947
    [Abstract] [Full Text] [Related]

  • 60. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
    Engel JB, Keller G, Schally AV, Toller GL, Groot K, Havt A, Armatis P, Zarandi M, Varga JL, Halmos G.
    J Clin Endocrinol Metab; 2005 Jun 15; 90(6):3614-21. PubMed ID: 15784701
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.